HEALTHCARE: COMMISSION PROBES JOHNSON & JOHNSON PURCHASE OF GUIDANT.

Regulators have started looking into the planned acquisition of US healthcare group Guidant by competitor Johnson & Johnson, worth roughly Euro 18 billion. Announcing the probe on April 25, the European Commission said that it had uncovered evidence of possible competition problems caused by overlaps in the markets for medical devices for the treatment of coronary and peripheral artery diseases and for cardiac...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT